This is a working overview of AOD-9604, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-01-02 and is reviewed periodically as new material appears.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
=== Category:EC 1.7 (act on other nitrogenous compounds as donors) === Category:EC 1.7.1 (with NAD+ or NADP+ as acceptor) Category:EC 1.7.2 (with a cytochrome as acceptor) Category:EC 1.7.3 (with oxygen as acceptor) Urate oxidase EC 1.7.3.3 Category:EC 1.7.7 (with an iron–sulfur protein as acceptor) Category:EC 1.7.99 (with other acceptors) Nitrite reductase EC 1.7.99.3 Nitrate reductase EC 1.7.99.4
Béjar stated that his expressions on the Navy were about a bomb plot against the Minister of War in 1975, and an attack against two Cuban fishing boats off the coast of Peru in 1977. Declassified documents show that the US Embassy suspected that these attacks were carried out by right-wing sectors of the Navy, which were unhappy with the military junta's close ties to Cuba at the time.
=== Composition === The Composition C-4 used by the United States Armed Forces contains 91% RDX ("Research Department Explosive", an explosive nitroamine), bound by a mixture of 5.3% dioctyl sebacate (DOS) or dioctyl adipate (DOA) as the plasticizer (to increase the plasticity of the explosive), thickened with 2.1% polyisobutylene (PIB, a synthetic rubber) as the binder, and 1.6% of a mineral oil often called "process oil". Instead of "process oil", low-viscosity motor oil is used in the manufacture of C-4 for civilian use. The British PE4 consists of 88.0% RDX, 1.0% pentaerythrite dioleate and 11.0% DG-29 lithium grease (corresp. to 2.2% lithium stearate and 8.8% mineral oil BP) as the binder; a taggant (2,3-dimethyl-2,3-dinitrobutane, DMDNB) is added at a minimum of 0.10% weight of the plastic explosive, typically at 1.0% mass. The newer PE7 consists of 88.0% RDX, 1.0% DMDNB taggant and 11.0% of a binder composed of low molecular mass hydroxyl-terminated polybutadiene, along with an antioxidant and an agent preventing hardening of the binder upon prolonged storage. The PE8 consists of 86.5% RDX, 1.0% DMDNB taggant and 12.5% of a binder composed of di(2-ethylhexyl) sebacate thickened with high molecular mass polyisobutylene. Technical data according to the Department of the Army for the Composition C-4 follows.
=== Pharmacokinetics === Cyproheptadine is well-absorbed following oral ingestion, with peak levels occurring after 1 to 4 hours. Its elimination half-life when taken orally is approximately 8.6 hours.
Sources: en.wikipedia.org
The human body needs iron for oxygen transport. Oxygen (O2) is required for the functioning and survival of nearly all cell types. Oxygen is transported from the lungs to the rest of the body bound to the heme group of hemoglobin in red blood cells. In muscle cells, iron binds oxygen to myoglobin, which regulates its release.
The rise has been exacerbated by the number of people sent to prison for their participation in the 2024 United Kingdom riots and the August Bank Holiday weekend, during which prisoners are not traditionally released. At one point during the preceding week, the number of spare prison places is believed to have fallen to less than 100. 31 August – A yellow weather warning for heavy rain and thunderstorms is issued for the following day for much of England and parts of east Wales.
=== Surgery === If the dilation of the aorta progresses to a significant-diameter aneurysm, causes a dissection or a rupture, or leads to failure of the aortic or other valve, then surgery (possibly a composite aortic valve graft or valve-sparing aortic root replacement) becomes necessary. Although aortic graft surgery (or any vascular surgery) is a serious undertaking it is generally successful if undertaken on an elective basis. Surgery in the setting of acute aortic dissection or rupture is considerably more problematic. Elective aortic valve/graft surgery is usually considered when aortic root diameter reaches 50 millimeters (2.0 inches), but each case needs to be specifically evaluated by a qualified cardiologist. New valve-sparing surgical techniques are becoming more common. As people with Marfan syndrome survive aortic root enlargement and dissections of the ascending aorta, other vascular repairs are becoming more common, e.g., repairs of descending thoracic aortic aneurysms and aneurysms of vessels other than the aorta, such as the subclavian arteries. The skeletal and ocular manifestations of Marfan syndrome can also be serious, although not life-threatening. These symptoms are usually treated in an appropriate manner for the condition, such as with pain medications or muscle relaxants. Because Marfan syndrome may cause asymptomatic spinal abnormalities, any spinal surgery contemplated on a person with Marfan should only follow detailed imaging and careful surgical planning, regardless of the indication for surgery.
Sources: en.wikipedia.org
Periostitis, also known as periostalgia, is a medical condition caused by inflammation of the periosteum, a layer of connective tissue that surrounds bone. The condition is most commonly chronic, and is marked by tenderness and swelling of the bone and pain.
27 March – A report clears Conservative MP Bernard Jenkin of breaching COVID-19 laws over his attendance at a "wine and nibbles" event on the Parliamentary estate in December 2020, which the report describes as socially-distanced with "business and social elements". 28 March – Keir Starmer and Angela Rayner launch Labour's campaign for the 2024 United Kingdom local elections at an event in Dudley. Honours are conferred on businessman and senior Conservative Party treasurer Mohamed Mansour, Farming Minister Mark Spencer and Shipley MP Philip Davies, all of who receive knighthoods, while former ministers Tracey Crouch and Harriett Baldwin are awarded damehoods. The announcement comes as part of an honours list published at the start of the Parliamentary recess. The Assisted Dying for Terminally Ill Adults (Scotland) Bill, a bill to legalise assisted dying in Scotland and drafted by Liberal Democrat MSP Liam McArthur, is introduced into the Scottish Parliament. 29 March – Sir Jeffrey Donaldson resigns as leader of the Democratic Unionist Party after being charged with rape and other historical sexual offences. Gavin Robinson is appointed interim leader until a new leader can be elected. 30 March – First Minister of Northern Ireland Michelle O'Neill says she is determined the Stormont Assembly and Executive will continue to function following the resignation of Jeffrey Donaldson as DUP leader. 31 March – The UK government says it will work alongside the Northern Ireland Executive to maintain stability at Stormont.
The cytochrome b5 reductase enzyme contains a typical oxidoreductase structure with a diaphorase binding domain complex for NADH and a FAD-binding domain. A three-stranded linker domain is present, as well as water-mediated hydrogen bonds, in order to biochemically connect the complex. Once cytochrome b5 reductase catalyzes electron transfer, the resulting reduced form of cytochrome b5 reduces the oxidized ferric ion of hemoglobin from Fe 3+ to Fe 2+. Mechanism: NADH + H+ + 2 ferricytochrome b5 -> NAD+ + 2 ferrocytochrome b5
The urine test may be a chromatographic immunoassay or any of several other test formats, home-, physician's office-, or laboratory-based. Published detection thresholds range from 20 to 100 mIU/mL, depending on the brand of test. Early in pregnancy, more accurate results may be obtained by using the first urine of the morning (when urine is most concentrated). When the urine is dilute (specific gravity less than 1.015), the hCG concentration may not be representative of the blood concentration, and the test may be falsely negative. The serum test, using 2-4 mL of venous blood, is typically a chemiluminescent or fluorimetric immunoassay that can detect βhCG levels as low as 5 mIU/mL and allows quantification of the βhCG concentration. The hCG levels grow exponentially after conception and implantation. hCG levels typically peak around weeks 8-11 of pregnancy and are generally higher in the first trimester compared to the second trimester. The following is a list of serum hCG levels: LMP is the last menstrual period dated from the first day of the last menstrual period
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.